Company / SG&A Expense
HealthEquity SG&A Expense History
FY2017-FY2026 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$103.7M
FY2026
5-year range
$60.6M / $132.3M
FY2022-FY2026
Trend
-13.6%
vs FY2025
Sector context
#133 of 158
Health Care
What the data says
HealthEquity's sg&a expense of $104M is lower than 84% of companies in the Health Care sector (FY2026). SG&A Expense has fluctuated over the past 10 years, ranging from $25M in FY2017 to $132M in FY2024.
Based on SEC 10-K filings.
$104M in FY2026 with a 5-year CAGR of +25.7%.
Improved from $132M to $104M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +0.0%
- 5-Year CAGR
- +25.7%
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 158This company $103.7M Sector average $175.9B
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +25.7%, indicating consistent growth.
- In FY2026, sg&a expense decreased 13.6% year-over-year.
- Ranks #133 out of 158 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 1.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | $103.7M | -13.6% |
| FY2025 | $119.9M | -9.3% |
| FY2024 | $132.3M | +27.6% |
| FY2023 | $103.7M | +71.2% |
| FY2022 | $60.6M | +83.3% |
| FY2021 | $33.0M | -60.9% |
| FY2020 | $84.5M | +39.5% |
| FY2019 | $60.6M | +83.3% |
| FY2018 | $33.0M | +31.6% |
| FY2017 | $25.1M | +24.6% |
As of FY2026 · SEC 10-K · Updated Jun 30, 2026